Skip to main content

£50m for tackling disparities in maternal healthcare

Funding from the National Institute for Health and Care Research (NIHR) has established the NIHR Inequalities Challenge: Maternity Disparities Consortium which will unite higher education, NHS, community and voluntary organisations to close the most critical gaps in maternal care, under the leadership of the University of Birmingham and Newcastle University.

The NIHR has committed £50 million over five years to drive forward the vital research led by clinicians, researchers, and communities across the consortium marking the most significant step forward in maternal health research in a generation.

The launch comes at a pivotal moment for maternity care in the UK, with national attention increasingly focused on improving safety, equity and women’s experiences of care.

The Government’s renewed Women’s Health Strategy highlights the need to improve care before and between pregnancies for underserved communities, against this backdrop, the consortium will generate the evidence, interventions and research capacity needed to help translate national ambition into practical, equitable improvements for women, babies and families.

University of Birmingham is leading on improving maternity care pathways across the antenatal, intrapartum and postnatal periods, ensuring that every woman receives the right care, at the right time, throughout her pregnancy journey.

Professor Joht Singh Chandan, Consortium Co-lead for Research, University of Birmingham said: “National attention on maternity safety and equity has never been greater, but ambition must now be matched by evidence and implementation. Through this consortium, we will work across the UK to understand what works, for whom and in what contexts, and to ensure that research leads to practical changes in care for the women, babies and families who need them most.”

Professor Judith Rankin OBE, Consortium Co-lead for Research and Capacity Development, Newcastle University said: “This funding represents a critical opportunity to make the step change we need to improve outcomes for women and their babies. Alongside the research, the Consortium will be investing in tomorrow’s research leaders today to ensure we have the capacity to deliver on improving pregnancy outcomes, access to, and experience of, care.”

Maternal health inequalities remain one of the most pressing challenges facing the NHS. In the UK, Black women continue to face a substantially higher risk of dying during or after pregnancy than white women, and women and families living in the most deprived communities continue to experience poorer outcomes. These inequalities are not inevitable.

Dr Vicky Hodgetts Morton, Associate Professor in Obstetrics at the University of Birmingham, Consultant Obstetrician and Co-Lead of the consortium’s Pregnancy, birth and early postnatal mental health theme said: “Too many women and families continue to experience avoidable disparities in maternity care and outcomes. This Consortium brings together researchers, clinicians, women, families and communities from across the UK with a shared commitment to tackling these inequalities.

“Working alongside colleagues at the University of Birmingham, including Professor Laura Jones, Professor Katie Morris, Professor Amy Grove, Dr Sarah Hillman and Dr Michelle Fisher, and partners across the Consortium, we are combining scientific expertise, lived experience and strong partnerships to better understand why these disparities occur and, more importantly, develop solutions that make a real difference.”

Dr Michelle Fisher, Senior Research Fellow in Applied Health at the University of Birmingham, and Emerging Co-Lead of the Racism, Discrimination and Intersectionality workstream said: “This research consortium is an important advancement in enabling researchers, service users, charities, communities, clinicians, and leaders to tackle racism and discrimination in the maternity care system across the UK.”

The NIHR Maternity Disparities Consortium will bring together clinicians, researchers, women, families and communities across the UK to develop practical, evidence-based solutions that can improve care, reduce avoidable harm and support better outcomes for mothers, babies and families.

The NIHR Maternity Disparities Consortium is a first of a series of NIHR Inequality challenge focused fundings calls secured by the University of Birmingham which includes the NIHR Cardiovascular Inequalities Challenge.

Key areas of research

Before and between pregnancies (preconception and interpregnancy care)

The consortium will examine how women and families can be better supported before pregnancy and between pregnancies. This includes improving access to advice and care that can help people prepare for pregnancy, manage existing health conditions and reduce risks before they build up.

Pregnancy, birth and early recovery after birth

Research will focus on improving care during pregnancy, birth and the early weeks after birth. This will include work on major causes of poor maternal health, such as high blood pressure, diabetes in pregnancy, obesity, perinatal mental health and complications during recovery after birth.

Care for babies and families after birth

The consortium will develop and test better ways to support babies and families who are at higher risk of poor outcomes. This includes improving follow up care after birth, strengthening links between hospital and community services, and supporting families as they move from maternity and neonatal care into longer term child and family support.

Access, communication and experience of care

The programme will look at how services can be easier to access, easier to understand and more responsive to women and families. This includes improving communication, language support, shared decision making and the overall experience of care, particularly for those who are least well served by current systems.

Tackling racism, discrimination and unfairness

The consortium will ensure that research directly addresses racism, discrimination and other forms of unfairness that affect maternity care and outcomes. This will be built into how interventions are designed, delivered and evaluated.

Working with communities

Women, families and community organisations will help shape the research from the beginning. The consortium will work with peer researchers, charities and community partners to make sure the work reflects real experiences and is useful to the people most affected by maternity inequalities.

Using data and evidence to drive change

The programme will use data, digital tools, health economics and real-world evaluation to understand what works, for whom and in what circumstances. This will help identify practical changes that can be delivered fairly and scaled across different parts of the UK.

Aston and SWB gynaecologists to investigate the use of weight-loss drugs in treating polycystic ovary syndrome

Dr Shagaf Bakour, a gynaecologist and director of medical education at Aston Medical School, has won an NHS research grant to investigate the use of weight-loss drugs in the treatment of polycystic ovary syndrome (PCOS).

The project was co-developed with Dr Hoda Harb, a consultant obstetrician and gynaecologist at fellow BHP member Sandwell and West Birmingham NHS Trust (SWB), who was a co-applicant on the funded grant.

PCOS is a common condition affecting up to one in ten women of reproductive age. It can cause irregular periods, make it harder to conceive, and lead to symptoms such as acne or excess hair growth due to higher levels of male hormones (androgens). It is also linked to weight gain and an increased risk of diabetes and heart and circulation problems.

A type of medicine called GLP-1 receptor agonists – more commonly known as weight-loss and blood sugar control drugs, such as Mounjaro (tirzepatide) and Ozempic (semaglutide) – are already widely used. These medicines may also help women with PCOS, who are more likely to experience obesity, insulin resistance, diabetes, and related heart and circulation problems.

In order to investigate this, Dr Bakour, Dr Harb and a multidisciplinary team from BHP members Aston University and SWBH have been awarded a £60,000 NHS research grant through the SWB NHS Research Fellowship scheme. The scheme supports projects which connect frontline clinicians and academic partners to improve patient care.

Initially, Dr Bakour and the team will review existing evidence of the use of GLP-1 receptor agonists for PCOS, to understand what is already known, identify important gaps, and determine which outcomes matter most to women and clinicians.

The next stage will involve securing the necessary governance and ethical approvals and linking fertility services, GP records and weight-management clinics to enable a real-world feasibility study. This will assess how these medicines are working in practice and whether they could lead to better, more consistent care for women living with PCOS.

Dr Bakour said: “The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care. The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways. Currently, care can vary, and women do not always get the same advice or treatment options. The research could lead to earlier support, better long-term health, and more joined-up care for a condition that affects many women but is still often overlooked.

“In the longer term, the work is intended to produce published evidence, support further external funding, and help prevent longer-term health problems linked to PCOS.”

Professor Elizabeth Hughes, director of research and development at SWB, said: “The effects of PCOS, which include infertility, are very emotive subjects and so we are delighted to support Dr Shagaf Bakour and Dr Hoda Harb with their research into possible treatments.

“We should be doing all we can within research and development to advance healthcare for women and to better help future generations with this condition.”

Lifesaving programme to prevent post-birth bleeding wins Times Higher Education STEM Award

A cost-effective intervention for postpartum haemorrhage, which has reduced maternal deaths worldwide by 60%, has won a major award in UK Higher Education.

The E-MOTIVE programme led by BHP founder-member the University of Birmingham and the World Health Organisation (WHO), with partners around the world, has been awarded Times Higher Education’s 2025 STEM award for best research in science, technology, engineering or mathematics.

Members of the E-MOTIVE team collect their award

The award was given to the low-cost set of interventions, which are being used to reduce deaths from childbirth-related bleeding – the leading cause of maternal mortality worldwide. It affects an estimated 24 million women each year and results in around 70,000 deaths – mostly in low and middle-income countries – equivalent to one death every seven minutes.

Professor Adam Devall from the University of Birmingham and an author of the study said: “We are delighted that E-MOTIVE has received recognition from the Times Higher Education awards, demonstrating the high calibre of research undertaken at the University of Birmingham.

“Childbirth-related bleeding is a major risk to life for women around the world, affecting an estimated 24 million women each year. E-MOTIVE is a powerful toolkit that is already being employed globally to dramatically reduce the numbers of women dying from excessive bleeding during childbirth.

“Continued international collaboration could see EMOTIVE prevent up to 20,000 maternal deaths a year, marking a revolution in maternal care.”

Following a landmark study published in the New England Journal of Medicine, the WHO has convened a group to draft its first official guidelines on bundled PPH care. It stated that bundled treatments could be provided for less than $1 per package – making them cheap enough to scale in low-income countries.

Four countries have now incorporated E-MOTIVE into their national clinical guidelines, with WHO updating its road map for addressing PPH. The Gates Foundation, which funded the trial, has pledged to invest a further $500 million (£375 million) into the treatments and further research as a result of its success.

Professor Arri Coomarasamy, Honorary Professor at the University of Birmingham who led the E-MOTIVE trial said: “E-MOTIVE has the power to radically improve women’s chances of surviving childbirth globally, helping them get the treatment they need when they need it.

“Time is of the essence when responding to postpartum bleeding, so interventions that eliminate delays in diagnosis or treatment should be gamechangers for maternal health.”

The award-winning research programme is part of the University of Birmingham’s work to end preventable death and illness in mothers affected by postpartum haemorrhage, miscarriage and other pregnancy-related conditions around the globe.

The University is leading the way in women’s health research by championing the need to test safe and effect medicine use during pregnancy and breastfeeding, including jointly leading Europe’s largest miscarriage research centre – the Tommy’s National Centre for Miscarriage Research.

The breadth of research expertise extends to other women’s health priorities, including ovarian cancer, where research has been instrumental in changing National Institute of Clinical Excellence guidelines regarding surgical approach.

New partnership with ABHI places Birmingham at the forefront of healthtech innovation

A new strategic partnership with the Association of British HealthTech Industries (ABHI) will see Birmingham Health Partners (BHP) work collaboratively to unlock innovation, accelerate research translation, and improve health outcomes across one of the UK’s most diverse regions.

ABHI is the UK’s leading industry association for health technology (HealthTech), supporting its members – including both multinationals and small and medium sized enterprises (SMEs) – to save and enhance lives through developing products from syringes and wound dressings to surgical robots, diagnostics and digitally enhanced technologies.

This new Memorandum of Understanding (MoU) between ABHI and BHP reflects a shared ambition to better connect the HealthTech industry with the academic and clinical excellence embedded across Birmingham and the wider region. The partnership will provide a more coordinated route for HealthTech companies to access world-leading expertise, infrastructure and patient insight, enabling technologies to be developed and evaluated with relevance to real-world settings.

Members of ABHI and BHP meet in Birmingham to formalise the MoU agreement

The agreement signposts BHP as the “front door” to the region – a clear entry point for HealthTech and life sciences companies looking to collaborate across the city’s extensive ecosystem which boasts globally ranked academic institutions and attracts significant health and life sciences research funding.

Importantly, Birmingham’s population provides a powerful testbed for innovation. As one of the youngest and most ethnically diverse cities in Europe, with a stable and rooted population, it offers the opportunity to generate insights and outcomes that are both locally relevant and globally applicable – presenting a unique opportunity to develop and scale interventions that reduce health inequalities and improve access for underserved groups.

Women’s health and mental health have been highlighted as critical areas of focus, with both ABHI and BHP committed to closing gender health gaps through innovative approaches and technology-enabled, whole-person models of care – as well as helping to reimagine mental health care, deliver earlier interventions, and support more equitable outcomes.

The partnership will measure success against three overarching priorities:

  • Demonstrating measurable improvements in clinical outcomes.
  • Ensuring that technologies are scalable and relevant to population health, not just individual conditions.
  • Addressing inequalities in access and experience of care, in support of a fairer, more resilient health system.

This collaboration builds on recent findings from the Health Innovation Network’s Size of the Prize analysis, which highlights the £278 billion economic potential that healthcare innovations could unlock if adopted at scale. It reflects ABHI’s strategic commitment to nurturing regional partnerships that not only drive economic growth, but also deliver tangible improvements in people’s lives.

Main image caption Executive Director of Birmingham Health Partners, Professor Neil Hanley, and ABHI Chief Executive, Peter Ellingworth, sign the MoU agreement

BHP’s health inequality lead set to head up NIHR Challenge Maternal Disparities Consortium

Professor Joht Singh Chandan – BHP’s heath inequalities lead and Clinical Professor of Public Health at the University of Birmingham – has been announced as co-lead of a new consortium which will research inequalities faced by expectant and new mothers.

The new NIHR Challenge Maternity Disparities Consortium is led by nine UK universities, all aiming to tackle inequalities in maternity care while building capacity for further research to help improve services over time. The consortium will help support professionals who plan and deliver services for women and babies across both health and social care.

Professor Chandan said: “I am honoured to take on the role of co-lead for the NIHR Maternity Disparities Consortium. Tackling inequalities in maternity care is a critical priority, and this consortium brings together a wealth of expertise to drive meaningful change.

“Our goal is to address disparities before, during, and after pregnancy by focusing on research that leads to real improvements in care for families and their babies across the UK. I am particularly looking forward to learning from and working alongside the communities most affected by these inequalities, ensuring that their insights shape our work and lead to lasting, impactful solutions.”

Professor Chandan will be joined by co-lead Dr Victoria Hodgetts Morton from the University of Birmingham, Dr Beck Taylor from Warwick University, Professor Will Parry-Smith from Keele University and Dr Marion Gibbon from Birmingham City Council.

Professor William Parry-Smith, Professor of Obstetrics and Gynaecology at Keele University, said: “I’m pleased to be leading Keele’s contribution to this nationally important work. Research and capacity building undertaken by the consortium will tackle the problem of maternity disparities. We have the opportunity in the West Midlands to understand and to then make a real difference crucially to improving maternity outcomes.”

Dr Beck Taylor, Clinical Associate Professor in Public Health, University of Warwick said: “This new consortium is an unparalleled opportunity to tackle the persistent maternity inequalities affecting life chances across the UK. These unacceptable differences are felt particularly by communities in our own region, the West Midlands. This consortium the first of its kind, and we cannot wait to get started on this programme. As part of the consortium we’ll bring together the communities, professionals and researchers to drive the change that women, babies and society urgently needs.”

Professor Marian Knight, Scientific Director for NIHR Infrastructure, said: “We are delighted by the level of engagement shown by researchers with this important research priority. I am confident we have an exceptional consortium to tackle the challenge of maternity inequalities; working in partnership with existing NIHR funded infrastructure and programmes. We look forward to working with the consortium and their collaborators across the UK to develop the final plans for their ground-breaking new research projects over the next few months.”

Health Minister Baroness Gillian Merron said: “Every woman should receive safe, personalised and compassionate maternity care, regardless of background. We are determined to tackle the stark and unacceptable inequalities in maternity services and are working with NHS England to urgently improve care. Government-funded research like this is crucial to driving positive change.

“This is part of our mission to build an NHS fit for the future by harnessing the full potential of our research and life sciences sector.”

You might also be interested in:

Birmingham launches pioneering trial to improve pregnancy outcomes for severe haemolytic disease

A pioneering study that took place at Birmingham Women’s Hospital has found an antibody that can improve the survival rate of unborn babies with rare, early-onset fetal anaemia, as a result of haemolytic disease of the fetus and newborn (EOS-HDFN).

Pregnant mothers have taken part in the UNITY trial, which has found that nipocalimab, an investigational, fully human, monoclonal antibody, has the potential to improve the survival rate of these babies.

BHP members the University of Birmingham (UoB) and Birmingham Women’s and Children’s NHS Foundation Trust (BWC) were a study site for a global, multicentre, open-label trial, in which nipocalimab was given for the treatment of pregnancies at high risk of severe EOS-HDFN, and evaluated safety, efficacy and the maternal metabolism of the monoclonal antibody.

Site investigator Mark Kilby, Emeritus Professor of Fetal Medicine at UoB and Honorary Consultant of Fetal Medicine at BWC said: “For mothers with severe HDFN the outcome not only of the condition but of the treatment, can be devastating. This is why the search for therapies to reduce the consequences of the maternal immune response has been focused on this cohort of women. The clinical study has found that nipocalimab is well tolerated and greatly increases the chance of unborn babies surviving severe EOS-HDFN, requiring less in-utero transfusion therapy.”

Haemolytic disease of the fetus newborn (HDFN), which is also sometimes referred to as Rhesus disease, is caused by a system of red blood cell antigens (most commonly of Rhesus D type) which raises the pathological antibody response in a pregnant person. These ‘pathological antibodies’ or alloantibodies can cross the placenta to the fetus and destroy its red cells, leading to progressive fetal anaemia and – if untreated – death of the fetus. 

Professor Kilby added: “These are fantastic results. In this group of pregnant women with severe HDFN, the medical management with nipocalimab has significantly reduced the need for early-onset in-utero fetal transfusion and improved the survival of these babies, reducing risks of miscarriage and stillbirth. Furthermore, and very importantly, nipocalimab seems to be well tolerated and safe for the mother and her unborn/newborn baby.   

“This research is a huge step forward for mothers who experience severe HDFN, as well as their partners, extended families, and of course, their children.”

Rosemary and Darren from Ireland were expecting baby Nessa when they took part in the clinical trial. Rosemary had had a previous in-utero transfusion for HDFN, and the couple had a child following treatment. Sadly, the couple lost a second baby after another in-utero transfusion. 

She was desperate to avoid another in-utero transfusion and was referred to the Fetal Medicine Centre at Birmingham Women’s Hospital eight weeks into her pregnancy after seeing news of the trial online and contacting her doctors at Dublin’s Rotunda Hospital. She had cell-free fetal DNA testing to confirm the baby was ‘suspectable’ to the antibodies she had produced. Rosemary then had maternal infusions of nipocalimab intravenously at weekly intervals from 14 to 35 weeks. 

Baby Nessa was born at 36 weeks weighing six pounds and 13 ounces and without the need for any IUTs.

Rosemary said: “When we were accepted onto the trial, we were both relieved and excited. Following the loss of our little girl Liliana, we were advised not to have any further pregnancies and we were devastated. This trial gave us hope of having another baby.”

“We were pregnant during the COVID lockdowns and as I was commuting from Ireland to Birmingham, it was a big worry but throughout our involvement in the trial, we felt supported, informed, understood and safe. We are forever grateful, the level of professionalism, compassion and empathy shown towards us is something we will never forget.” 

“Our two sons, Ollie and Joey now have a little sister, Nessa, who is a bubbly happy healthy four-year-old, full of mischief, giggles, and fun. To think the trial has given us what we believed was impossible, is a dream come true. To hear the trial has also given others living healthy children is fantastic. In a situation where we, like so many others felt was hopeless, to now know there is a treatment is like a miracle.”